JACKSONVILLE, FL – April 8, 2026 – Today, Johnson & Johnson announced ACUVUE VITA for Astigmatism is available in expanded parameters, bringing patient coverage of the product up to nearly 96%.[1]* Across the full power range (-9.00 to +6.00), ACUVUE VITA for Astigmatism will now offer around the clock coverage (in 10 degree increments up to -2.75D cylinder. The new parameters are available for order in the United States, Canada and the Caribbean.
“We remain deeply committed to meeting the evolving needs of Eye Care Professionals and patients in need of vision correction,” said Shawn Millerick, President, Americas Vision Care, Johnson & Johnson. “The expanded ACUVUE VITA for Astigmatism offering now covers nearly 96%1* of astigmatic eyes, giving more patients access to an affordable, comfortable monthly contact lens.”
The ACUVUE VITA Brand Family offers new monthly wearers exceptional comfort all month long and at an amazing value now with an extensive range of parameters to help meet the vision needs of astigmatic patients.[2],[3] Only ACUVUE lenses feature BLINK STABLIZED®DESIGN4 for exceptional vision, stability, and comfort[4]:
- Four stability zones4 harness the power of the eye blink and are more resistant to the effects of gravity vs ballasted designs[4]
- Prism-free optic zone avoids vertical prism disparity challenges[5]** for monocular astigmats likes headaches and discomfort, unlike traditional ballasted designs
In addition to expanded coverage for astigmatic patients, the ACUVUE VITA family of products now offers enhanced rewards for new patients, alongside new wearer-inspired packaging scheduled to debut later this year. For more information about ACUVUE® VITA® for Astigmatism visit: https://www.jnjvisionpro.com/en-us/products/acuvue-vita-astigmatism/
###
Important Safety Information
ACUVUE® VITA® Contact Lenses are indicated for vision correction as a daily wear lens with one-month recommended replacement. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Lenses should not be prescribed if patients have any eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. Consult the package insert for complete information. Complete information is also available from Johnson & Johnson Vision Care, Inc. by calling 1-800- 843-2020, or by visiting www.jnjvisionpro.com.
Third party trademarks are the property of their respective owners.
About Vision at Johnson & Johnson
Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients’ eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at clearvisionforyou.com, follow @JNJVision on Twitter, Johnson & Johnson | Vision on LinkedIn, and @JNJVision on Facebook.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://www.jnjmedtech.com/en-US/. Follow us at @JNJMedTech and on LinkedIn.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to expanded parameters for ACUVUE VITA for Astigmatism. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
* Actual coverage is 95.5%
** *Vertical phorias possibly caused by prism dissociation due to the presence of induced optical prism is a relevant factor for practitioners to consider when fitting toric contact lenses for monocular astigmats or those requiring a mix of toric soft contact lens designs. Clinical studies have not been done to fully characterize the clinical effects of differences in base down prism among different contact lenses.
© Johnson & Johnson and its affiliates 2026
2026PP07327